Key Takeaways Viatris acquired Aculys Pharma to enhance its neurological drug portfolio and Japan presence.The deal grants Viatris exclusive rights to pitolisant and Spydia, strengthening its CNS portfolio.Pitolisant and Spydia support Viatris' goal to grow in high-impact therapeutic areas in Asia-Pacific.Viatris (VTRS) announced the acquisition of Tokyo-based Aculys Pharma, a clinical-stage biopharmaceutical company specializing in neurological therapies. The deal grants Viatris the rights to develop and c ...